Quantcast

Latest Phenols Stories

2014-07-22 08:31:15

RALEIGH, N.C., July 22, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) announced that its Board of Directors has appointed Charles J. (Chuck) Bramlage and Dr. Barry I. Feinberg as members of the Board. http://photos.prnewswire.com/prnvar/20110217/CL49801LOGO Mr. Bramlage is a veteran pharmaceutical industry executive with extensive experience in marketing, sales and other commercial functions. He is currently the Chief Executive Officer of...

2014-07-16 08:28:03

FDA also approves the use of two Butrans patches for dose adjustments in appropriate chronic pain patients STAMFORD, Conn., July 16, 2014 /PRNewswire/ -- Purdue Pharma L.P. announced that the U.S. Food & Drug Administration (FDA) approved a new 7.5 mcg/hour dosage strength of Butrans(®) (buprenorphine) Transdermal System CIII. Five strengths of Butrans will now be available: 5 mcg/hour, 7.5 mcg/hour, 10 mcg/hour, 15 mcg/hour and 20 mcg/hour. The Butrans Transdermal System is also...

2014-07-15 23:14:30

Avail is conducting a Phase 2, randomized, placebo-controlled clinical research study to evaluate the efficacy, safety and pharmacokinetics of an experimental spray treatment for qualified participants with mild to moderate osteoarthritis (OA) of the knee. DeLand, FL (PRWEB) July 15, 2014 *To see if you qualify for this Osteoarthritis Clinical Trial in DeLand, visit Avail Clinical Research on the web (http://www.availclinical.com) or contact us directly at (386) 785-2404. There is no cost...

2014-07-15 16:27:44

LONDON, July 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Pristiq (Major Depressive Disorder) - Forecast and Market Analysis to 2023https://www.reportbuyer.com/product/2166742/Pristiq-Major-Depressive-Disorder---Forecast-and-Market-Analysis-to-2023.htmlPristiq (Major Depressive Disorder) - Forecast and Market Analysis to 2023SummaryMajor depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded...

2014-07-10 08:27:14

First and only FDA approved naloxone product specifically indicated for emergency therapy in settings where opioids may be present. RICHMOND, Va., July 10, 2014 /PRNewswire/ -- Kaleo, a privately-held pharmaceutical company headquartered in Richmond, Virginia, today announced the United States (U.S.) commercial availability of EVZIO for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. EVZIO is not a...

2014-07-09 08:27:41

Name Change to Reflect the Operations of the Company after the Completion of the Public Transaction NEW YORK, July 9, 2014 /PRNewswire/ -- Camp Nine, Inc., (OTCBB: CMPE), a Nevada corporation which conducts its operations through Relmada Therapeutics, Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has changed its corporate name to Relmada Therapeutics, Inc. The name change began with the Nevada Secretary of State...

2014-07-08 08:31:53

DUBLIN, July 8, 2014 /PRNewswire/ -- Perrigo Company (NYSE: PRGO; TASE) today announced that it was the first to receive final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for ibuprofen and phenylephrine hydrochloride tablets, 200 mg/10 mg (over-the-counter), the store brand equivalent to Advil(®) Congestion Relief Tablets, 200 mg/10 mg. Perrigo expects to begin shipments of the product prior to the upcoming cough/cold/flu season....

2014-07-07 08:27:32

- Pre-NDA meeting scheduled with FDA in July DUBLIN and RALEIGH, N.C., July 7, 2014 /PRNewswire/ -- Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) (TSX: ENL), and BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced today positive top-line results from its pivotal Phase III efficacy study of BEMA buprenorphine in opioid-experienced patients. BEMA buprenorphine is being developed for the management of pain severe enough to require...

Southern Doctors Write More Opioid Painkiller Prescriptions Than Their Northern Counterparts Do
2014-07-03 06:40:59

redOrbit Staff & Wire Reports - Your Universe Online Opioid painkiller use in the US vary greatly by region, with most of the highest-prescribing states being located in the southern part of the country, the Centers for Disease Control and Prevention (CDC) has revealed in a new report. According to the study, health care providers from southern US states typically had the highest per-person rate of opioid or narcotic pain reliever prescriptions, which include drugs such as Vicodin...

2014-07-01 10:49:46

Boston University Medical Center The results of a new study demonstrate that starting hospitalized patients who have an opioid (heroin) addiction on buprenorphine treatment in the hospital and seamlessly connecting them with an outpatient office based treatment program can greatly reduce whether they relapse after they are discharged. Led by researchers at Boston Medical Center (BMC), the study shows the important role that providers play in offering these patients addiction treatment...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related